Interview: André Choulika – Chairman and CEO, Cellectis, France
André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution;…
Amatsigroup, as a CDMO (Contract Development and Manufacturing Organisation), provides services throughout both preclinical and clinical phases. With more than 200 highly-qualified staff and a diversified portfolio of over 300 clients, Amatsigroup is poised to become the leading French company in its sector. Acquisitions have been an important element of the company’s build-up strategy. In January 2016, they completed the acquisition of the Belgian Q-Biologicals, specializing in Bio-process development & Bio-manufacturing. Amatsigroup generates annual sales of 33 million euros (37.1 million USD) and contributes, every year, to the development and registration of more than 30 pharmaceutical products for its clients.
The Group operates from facilities based in the South of France, Belgium and in the US.
Contact
Parc de Génibrat, 31 470 Fontenilles – FRANCE
0033 5 62 14 73 14
André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution;…
Serving as the leader of two companies – Platine, a CRO, and Indicia, a CMO – Stephane Legastelois, in his own words, challenges himself by wearing two different hats. Offering…
Laurence Comte-Arassus, president of Medtronic France, reveals how after the global acquisition of Covidien in January 2015, France is now their second largest subsidiary in the EMEA region; how Medtronic´s…
Nicolas Bardonnet, general manager of Promega France, reveals how France hosts both their European application laboratory and European training centre, offering a wide range of courses in molecular biology, cell…
The October 2015 merger between Houston, TX-based Cyberonics and Milan, Italy-based Sorin has led the creation of LivaNova, a medical device manufacturer active in the fields of cardiac surgery, neuromodulation…
Philippe Chêne, President of Winncare, reveals how he has led the company to be a force to be reckoned with as an advocate of preventative healthcare. An exemplary case of…
Christophe Lala, general manager of Western Europe at GE Healthcare, reveals how today the challenge is to ensure that all patients in France have access to the same medical pathway;…
Emmanuelle Ribot-Mariotte, general manager of Alfa Wassermann Pharma France, reveals how over the past year the company has been working hard on a new innovative treatment for hepatic encephalopathy, Rifaximin-alpha…
Finding success in the shadows of Big Pharma and large research facilities, CleveXel serves as a bridge in the industry, specializing on selecting promising molecules for investment, and developing them…
Prof. Thierry Philip, President of Institut Curie, is proud of the model that the institute is thriving for: excellent science and research in all forms, from the most basic to…
The recently appointed general manager of Galderma France, reveals the company’s ambitious objective for the next ten years: to increase sales from two to ten billion Euros (2.18 billion USD to…
Eric Goupil reveals how the global CMO market has expanded considerably over recent years, with a move towards a more strategic mind-set in the pharmaceutical industry. Unither´s business model is…
See our Cookie Privacy Policy Here
